Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review

Johansson, Saga; Rosengren, Annika; Young, Kate; Jennings, Em

doi:10.1186/s12872-017-0482-9

Cited by 236 publications

(177 citation statements)

References 33 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of comorbidities such as hypertension and diabetes, was high in the study population, and as shown in other studies, diabetes is a significant risk factor for recurrent events . In the Hoorn cohort study, the incidence of a recurrent cardiovascular event during approximately 4 years of follow‐up was 60% higher for individuals with diabetes compared with those without, and higher glycated hemoglobin was one of the predictive risk factors for a recurrent event .…”

Section: Discussionsupporting

confidence: 62%

“…In the Hoorn cohort study, the incidence of a recurrent cardiovascular event during approximately 4 years of follow‐up was 60% higher for individuals with diabetes compared with those without, and higher glycated hemoglobin was one of the predictive risk factors for a recurrent event . A recent systematic review of morbidity and mortality in patients who survived for at least 1 year following MI found that older age, history of stroke, and comorbidities, including diabetes, hypertension, peripheral artery disease, and renal disease, were associated with a greater risk of recurrent cardiovascular events or death …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population

Peng

Wang

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Background Survivors of myocardial infarction (MI) or ischemic stroke (IS) are at high risk for subsequent cardiovascular events. Hypothesis Older patients with prior MI or IS are at risk for recurrent cardiovascular events, and comorbidities such as diabetes may increase this risk. Methods Two cohorts were studied in a retrospective Medicare 20% random sample—a 2008 cohort with up to 6 years of follow‐up (MI, N = 26 460; IS, N = 17 566) and a 2012 cohort with 1 year of follow‐up (MI, N = 26 548; IS, N = 17 728). Results In older patients who survived an event of MI or IS (2012 cohort), 7.2% had a recurrent MI and 6.7% had a recurrent IS in the first year; 32% died. Accounting for multiple recurrent events (2012 cohort), the event rates per 100 patient‐years were 11.6 and 10.2 for the MI and IS cohorts, respectively. Cumulative incidence of recurrence (2008 cohort) increased from 7.7% at 1 year to 14.3% at 6 years for recurrent MI and from 6.7% at 1 year to 13.4% at 6 years for recurrent IS. Comorbid diabetes (2012 cohort) was significantly associated (adjusted risk ratio) with MI recurrence (1.44) and risk of coronary revascularization (1.23) in the MI cohort and with IS recurrence (1.26) in the IS cohort. Conclusion In this older population with prior MI or IS, high rates of recurrent cardiovascular events and multiple recurrent events were observed. These findings highlight the need for aggressive intervention for secondary prevention and management of comorbidities in high‐risk patients, particularly those with diabetes.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population

Peng

Wang

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…It is typically caused by the blockage of coronary artery, leading to the chest pain, weakness, diaphoresis, dyspnea, palpitation and even unconsciousness. The incidence of MI is declining in most countries with the development of therapeutic approaches [1]. However, the burden of MI is generally increasing as a result of the aging world population, population growth, and the rising prevalence of long-term survivors of MI [2].…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Gong

Chang

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Astragaloside IV (AS-IV), a traditional Chinese medicine isolated from Astragalus membranaceus, has been shown to exert cardioprotective effect previously. This study aimed to reveal the effects of AS-IV on hypoxia-injured cardiomyocyte. Methods: H9c2 cells were treated with various doses of AS-IV for 24 h upon hypoxia. CCK-8 assay, flow cytometry/Western blot, and qRT-PCR were respectively conducted to measure the changes in cell viability, apoptosis, and the expression of miR-23a and miR-92a. Sprague–Dawley rats were received coronary ligation, and were administrated by various doses of AS-IV for 14 days. The infarct volume and outcome of rats followed by ligation were tested by ultrasound, arteriopuncture and nitrotetrazolium blue chloride (NBT) staining. Results: We found that 10 μg/ml of AS-IV exerted myocardioprotective effects against hypoxia-induced cell damage, as AS-IV significantly increased H9c2 cells viability and decreased apoptosis. Interestingly, the myocardioprotective effects of AS-IV were alleviated by miR-23a and/or miR-92a overexpression. Knockdown of miR-23a and miR-92a activated PI3K/AKT and MAPK/ ERK signaling pathways. Bcl-2 was a target gene for miR-23a, and BCL2L2 was a target gene for miR-92a. In the animal model of myocardial infarction (MI), AS-IV significantly reduced the infarct volume, ejection fraction (EF), shortening fraction (FS) and LV systolic pressure (LVSP), and significantly increased left ventricular end-diastolic internal diameter (LVEDd). And also, the elevated expression of miR-23a and miR-92a in MI rat was reduced by AS-IV. Conclusion: AS-IV protected cardiomyocytes against hypoxia-induced injury possibly via down-regulation of miR-23a and miR-92a, and via activation of PI3K/AKT and MAPK/ERK signaling pathways.

show abstract

“…21 In the case of MI, survivors are at high risk for death, or recurrent MI and other cardiovascular events. 25,26 Although, patient outcome is improving, there is considerable burden on healthcare systems and incidence is increasing in an aging and obese population.…”

Section: Future Perspectivesmentioning

confidence: 99%

Antibody Based Therapy in Coronary Artery Disease and Heart Failure

Fiedler¹

2017

Heart Res Open J

View full text Add to dashboard Cite

The function of the immune system is to protect the host against disease. Antibodies are a key part of the adaptive response, recognising specific antigens and invading pathogens and marking them for destruction or blocking their activities. A mechanistic and molecular understanding of this process has allowed researchers to harness their natural function. They are now routinely used as a diagnostic tool in the clinic and in research to investigate pathological signalling. More recently, antibodies have been utilised for another application -therapy. Antibody based therapy is one of the newest and fastest growing with nearly 70 approved drugs to date and over 1000 in clinical trials. Investment from the pharmaceutical sector shows no signs of abating and this technology is now widely accepted for treating cancer, autoimmune and infectious diseases. In the context of the cardiovascular system however, antibody therapies are relatively limited. This review summarises the monoclonal antibodies approved for clinical use or currently in clinical trials for treating cardiovascular disorders. Presently, coronary artery disease, heart failure and transplant are the main indications, and monoclonal antibody therapies are discussed in the context of their specific applications.

show abstract

Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review

Cited by 236 publications

References 33 publications

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

Antibody Based Therapy in Coronary Artery Disease and Heart Failure

Contact Info

Product

Resources

About